A Retrospective Drug Utilization Study of Antiplatelet Drugs in Patients with Ischemic Heart Disease

Objective: Acute coronary syndrome is a clinical condition encompassing ST segments elevation myocardial infraction, Non ST segment is elevation myocardial infraction and un stable angina is characterized by ruptured coronary plaque, stress and myocardial injury. Angina pectoris is a pressure like pain in the chest that is induced by exertion or stress and relived with in the minute after cessation of effort or using sublingual nitroglycerin. The present research was undertaken to study the drug utilization pattern of antiplatelet drugs for the ischemic heart disease in a tertiary care hospital. Method: The present study is retrospective drug utilization study and study period is 6months. The data is collected from the discharge case sheet of general medicine department from medical department Rajiv Gandhi institute of medical sciences, Kadapa. The tentative sample size fixed was 250 patients. Out of 250 cases 19 cases was excluded because of unrelated data. Results: A total of 250 prescriptions were collected for the study according to the inclusion criteria 233 prescriptions were diagnosed with ischemic heart disease 17 prescriptions were excluded due to unrelated information. out of 233 prescriptions 128 are male (54.9%) and 105 patients are were female (45%). According to the gender distribution, the prevalence of ischemic heart disease in males are 90 (70.31%) and females are 39 (37.1%). In the same way the prevalence of ischemic heart disease along with cerebrovascular disease in males are 39 (29.6%) and females are 66 (62.6%). Conclusion: We found that 94.8% of drug utilization of antiplatelet drugs was achieved in the Rajiv Gandhi institute of medical sciences, Kadapa from 2011-2012.

Authors:

• K. Jyothi
• T. S. Mohamed Saleem
• L. Vineela
• C. Gopinath
• K. B. Yadavender Reddy

Keywords:

• Angina pectoris
• aspirin
• clopidogrel
• myocardial infarction.

References:

[1] Najeeb, Q., S. Hamid, A.H. Khan. 2014. Novel Biomarkers in Assessing
Cardiovascular Status in Acute Myocardial Infarction. J. Cardiovas. Dis.
Res. 5(4): 22-27.
[2] Kristian, T., S.A. Joseph, S.J. Allan, L.S. Maarten, R.C. Bernard, D.W.
Harvey. 2012. Third Universal Definition of Myocardial Infarction. J.
Am. Coll. Cardiol. 60(16):1581-98.
[3] Indrayan A. 2004. Forecasting cardiovascular disease cases and
associated mortality in India. National Commission for Macroeconomics
and Health, Government of India: New Delhi. 3.
[4] Enas, E.A., S. Kannan. 2008. How to beat the heart disease epidemic
among South Asians. A prevention and management guide for Asian
Indians and their doctors. Downers Grove: Advanced Heart Lipid Clinic
USA, 2007. Indian Heart J 60: 161–175.
[5] Ajay, S.V., D. Prabhakaran. 2010. Coronary Heart Disease in Indias.
Implications of the INTERHEART study. Indian Journal of Medical
Research 132: 561-566.
[6] Fahimi, F., S. Baniasadi, N. Behzadniac, F. Varahrama, L.G. Tabatabaie.
2008. Enoxaparin Utilization Evaluation: An Observational Prospective
Study in Medical Inpatients. Iranian. J. Pharmaceutical. Res. 7 (1): 77-82
[7] WHO 2014, http://apps.who.int/medicinedocs/en/d/Js4876e
[8] John, L.J., P. Devi, S. Guido. 2012. Utilization of antihypertensive
medications among the critically ill patients. RJPBCS 3(3):650-654
[9] WHO 2011. Cardiovascular diseases (CVDs) Fact sheet No. 317,
September.
[10] Ajay, S.V., Prabhakaran, D. 2010. Coronary Heart Disease in Indias.
Implications of the INTERHEART study. Indian Journal of Medical
Research 132: 561-566.
[11] Balady, G.J., Williams, M.A., Ades, P.A., Bittner, V., Comoss, P.,
Foody, J.A.M. 2007. Core components of cardiac
rehabilitation/secondary prevention programs. Circulation 115: 2675–
2682.
[12] Fox, K. 2008. Stable angina pectoris. In: Compendium of Abridged ESC
Guidelines. Nice, France: European Society of Cardiology pp 77–89.
[13] National Institute of Clinical Excellence 2007. CG48. MI: Secondary
prevention: understanding NICE guidelines.
[14] World Health Organisation. 2002. Wellcome Trust Meeting Report.
Secondary prevention of non-communicable diseases in low and middle
income countries through community-based and health service
interventions. WHO Document No. WHO/EDM/2000. Geneva,
Switzerland: World Health Organization.
[15] Beaglehole, R., Epping-Jordan, A., Patel, V., Chopra, M., Ebrahim, S.,
Kidd, M., Haines, A. 2008. Improving the prevention and management
of chronic disease in low-income and middle-income countries: a
priority for primary health care. Lancet 372: 940–949.
[16] De Wilde, S., Carey, I.M., Richards, N., Whincup, P.H., Cook, D.G.
2008. Trends in secondary prevention of ischemic heart disease in the
UK 1994–2005: use of individual and combination treatment. Heart 94:
83–88.
[17] Newby, L.K., LaPointe, N.M.A., Chen, A.Y., Kramer, J.M., Hammill,
B.G., DeLong, E.R. 2006. Long term adherence to evidence based
secondary prevention therapies in coronary artery disease. Circulation
113: 203–212.
[18] Chauhan, S., Aeri, B.T. 2013. Prevalence of cardiovascular disease in
India and it is economic impact- A review. Int. J. Sci. Res. Pub. 3(10):1-
5.
[19] Padmavati, S. 2014. Epidemiology of Cardiovascular Disease in India. J.
American. Heart. Association. 711-717.
[20] Sandozi, T., Nausheen, F. 2010. Drug utilization study in ischemic heart
diseases associated with diabetes and hypertension. Int. J. Pharma. Bio.
Sci. 1 (3):1-4.
[21] Jhaveri, B. N., Patel, T. K., Barvaliya, M. J., & Tripathi, C. B. 2014.
Drug utilization pattern and pharmacoeconomic analysis in geriatric
medical in-patients of a tertiary care hospital of India. Journal of
Pharmacology & Pharmacotherapeutics, 5(1), 15–20.
http://doi.org/10.4103/0976-500X.124411
[22] Ghosh, A., Kumar, A. 2012. Drug utilization study in patients of acute
coronary syndrome on follow-u visits at a tertiary care centre in Kolkata.
Asian. J. Pharmacy. Life. Science. 2(2): 155-165.